Cost-effectiveness analysis of eliminating industrial and all trans fats in England and Wales: modelling study by Pearson-Stuttard, Jonathan et al.
Cost-effectiveness analysis of eliminating industrial and all trans fats in England and
Wales: modelling study
Pearson-Stuttard, Jonathan; Hooton, William ; Critchley, Julia; Capewell, Simon; Collins,
Marissa; Mason, Helen; Guzman-Castillo, Maria; O'Flaherty, Martin
Published in:







Link to publication in ResearchOnline
Citation for published version (Harvard):
Pearson-Stuttard, J, Hooton, W, Critchley, J, Capewell, S, Collins, M, Mason, H, Guzman-Castillo, M &
O'Flaherty, M 2017, 'Cost-effectiveness analysis of eliminating industrial and all trans fats in England and Wales:
modelling study', Journal of Public Health, vol. 39, no. 3, pp. 574-582. https://doi.org/10.1093/pubmed/fdw095
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please view our takedown policy at https://edshare.gcu.ac.uk/id/eprint/5179 for details
of how to contact us.
Download date: 03. Jan. 2022
1 
 
COST EFFECTIVENESS ANALYSIS OF ELIMINATING INDUSTRIAL AND ALL TRANS FATS 
IN ENGLAND AND WALES: MODELLING STUDY 
Jonathan Pearson-Stuttard1,4, William Hooton2, Julia Critchley3, Simon Capewell4, Marissa Collins5, 
Helen Mason5, Maria Guzman-Castillo4, Martin O’Flaherty4 
 
Author affiliations: 
1 – School of Public Health, Imperial College London, London, UK 
2 – Pembroke College Alumni, University of Oxford, Oxford, UK 
3 - Population Health Research Institute, St George’s, University of London, London, UK 
4 – Division of Public Health and Policy, University of Liverpool, Liverpool, UK 




Phone: 00447736279777   
Fax:   
e-mail:  j.pearson-stuttard@imperial.ac.uk 
 
Jonathan Pearson-Stuttard MA (Oxon), BM BCh, Academic Clinical Fellow and Public Health Specialty Registrar 
Address: Department of Public Health and Primary Care, Imperial College London, 3
rd
 Floor, Reynolds Building, St 
Dunstan’s Road, London. W6 8RP 
William Hooton, BA, CFA, Economics and Management Graduate 
Address: Pembroke College, Pembroke Square, St Aldates, Oxford, OX1 1DW 
Julia Critchley MSc, PhD, Professor of Epidemiology 
Address: Population Health Research Institute, St George's, University of London, Cranmer Terrace, London SW17 0RE 
Simon Capewell MD DSc, Professor of Clinical Epidemiology 
2 
 
Address: Public Health and Policy, Institute of Psychology, Health and Society, University of Liverpool, Liverpool, L69 3GB 
Marissa Collins, Researcher in Health Economics,  
Address: Yunus Centre of Social Business and Health, Glasgow Caledonian University, Cowcaddens Road, Glasgow, G4 0BA 
Helen Mason, Senior Lecturer in Health Economics,  
Address: Yunus Centre of Social Business and Health, Glasgow Caledonian University, Cowcaddens Road, Glasgow, G4 0BA  
Maria Guzman-Castillo Research Associate in Public Health Modelling 
Address: Public Health and Policy, Institute of Psychology, Health and Society, University of Liverpool, Liverpool, L69 3GB 
Martin O’Flaherty MD, PhD, Senior Lecturer in Epidemiology and Health Services Research 
Address: Public Health and Policy, Institute of Psychology, Health and Society, University of Liverpool, Liverpool, L69 3GB 
 
 
Keywords: socioeconomic status, coronary heart disease burden, modelling, cost-effectiveness, trans fats 
Journal Subject code:  










Copyright/license for publication 
3 
 
The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all 
authors, an exclusive license (or non exclusive for government employees) on a worldwide basis to BMC  
Publishing Group Ltd and its licensees, to permit this article (if accepted) to be published in Journal of Public 





Acknowledgements: We thank the UCL team who helped develop the IMPACTsec version of our IMPACT 
model: Maddy Bajekal, Shaun Scholes and Rosalind Raine.  
 
Contributors: JPS, SC and MoF conceived the idea of the study. SC and JC developed the original IMPACT CHD 
model. JPS and WH led the analysis supervised by MoF and JC, and generated the results.  JPS drafted and 
finalised the paper with input from WH, MGC, HM, MC, SC, MoF and JC. All authors contributed to the analysis, 
intellectual content, critical revisions to the drafts of the paper and approved the final version. SC is the 
guarantor and affirms that the manuscript is an honest, accurate and transparent account of the study being 
reported. 
 
Ethical approval: None required as secondary analysis of publicly available data. 
 
Funding sources: This project was funded by the MRC NPRI3 scheme, & EU MedCHAMPS project financed by EC 
FP7 grant no. 223705. Title: Prevention IMPACT: developing and evaluating economic models for planning 













Coronary Heart Disease (CHD) remains a leading cause of UK mortality. Dietary trans fats (TFA) represent a powerful 
CHD risk factor.  However, UK efforts to reduce intake have been less successful than other nations. We modelled 
the potential health and economic effects of eliminating industrial and all TFA up to 2020.   
Methods  
We extended the previously validated IMPACTsec model, to estimate the potential effects on health and economic 
outcomes of mandatory reformulation or a complete ban on dietary TFA in England and Wales from 2011-2020.  
We modelled two policy scenarios:  
   1) elimination of industrial TFA consumption, from 0.8%-0.4% daily energy   
   2) elimination of all TFA consumption, from 0.8%-0%  
Results 
Elimination of industrial-TFA across the England and Wales population could result in approximately 1,600 fewer 
deaths per year, with some 4,000 fewer hospital admissions; gaining approximately 14,000 additional life years. 
Health inequalities would be substantially reduced in both scenarios.  
 
Elimination of industrial-TFA would be cost saving. This would include approximately £100m saved in direct 
healthcare costs. Elimination of all TFA would double the health and economic gains. 
 
Conclusions 
Eliminating industrial or all UK dietary intake of TFA could substantially reduce CHD mortality and inequalities, 




Cardiovascular disease (CVD) (coronary heart disease (CHD) and stroke), continues to be a major cause of 
mortality and morbidity in the UK, and globally. Mortality rates for CVD have halved over the past two 
decades[1], but despite this, approximately 35% of total UK deaths remain attributable to CVD. CVD is 
estimated to cost the UK economy £30bn annually[2] with some £14bn of this spent on healthcare. CHD costs 
have increased from £1.75bn in 1999, to £2bn in 2005[3], with the statin bill alone exceeding £840m in 
2006[4], whilst statin prescriptions had increased by almost 50% by 2012[5]. These costs are expected to 
continue to increase in the coming decades. Major risk factors for CHD are diet, smoking, alcohol excess and 
physical inactivity[6]. Within diet, key factors include suboptimal fruit and vegetable intake, excess salt, sugar, 
saturated fats, and trans fatty acids (TFA). TFA are more harmful to CHD than any other macronutrient.  
TFA consumption comprises industrial TFA (approximately 0.8% daily energy intake in the UK), and 
ruminant TFA (approximately 0.4% daily energy intake). Industrial TFA are unsaturated fatty acids with at least 
one double bond in the trans configuration, formed during the partial hydrogenation of vegetable oils. This 
process is utilised in the production of margarines, commercial cooking and food manufacturing processes. 
The partial hydrogenation process converts the vegetable oil into a solid fat with stability during packing,  
enhanced palatability and longer shelf life, hence profitability. The major sources of dietary TFA in the UK are 
bakery products, spreads, packaged snack foods and deep-fried fast foods. Naturally occurring ruminant TFA, 
such as in meats, dairy and other ruminant products are produced by the action of bacteria in the ruminant 
stomach. The role of ruminant TFA upon CHD risk is much less well characterised than industrial TFA; initially 
thought to be relatively harmless, it now appears this may have been under-estiamted owing to low intake 
levels[7].  
Industrial TFA substantially increase CHD risk by raising LDL-cholesterol (bad cholesterol), reducing HDL-
cholesterol (good cholesterol), causing systemic inflammation and adversely affecting endothelial cell 
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function[8]. TFA increase CHD risk more than any other macronutrient[7], whereby every 1% increase in daily 
energy obtained from TFA raises CHD mortality by 12%[8]. Consumption of TFA has fallen across the 
developed world over the past decade, reaching approximately 0.8% (2 grammes)[10] of daily energy intake in 
the UK. This reduction has only been achieved by sustained pressure from the UK Food Standards Agency, 
reformulation efforts by some companies and voluntary content labelling[11]. The effectiveness of these 
voluntary measures appears to be decreasing given the decline in the rate of TFA intake reduction since 
2007[12].  Labelling is probably not the answer - being slow, bureaucratic and of limited effectiveness[13].    
Several other policies, ranging in efficacy, have been utilised to successfully reduce dietary TFA in countries 
across the globe. These include voluntary self regulation, and local or national legislation[14]. TFA bans in 
restaurant food in New York City eventually led to national-wide reformulation and a halving of population TFA 
levels in the USA[12], however can have inequitable effects[14].  
The most effective policies have been national legislative bans, such as those seen in Denmark, Iceland, 
Austria and Switzerland. Moreover, we recently quantified the potential health effects upon the England and 
Wales population of reductions in TFA intake by 0.5% and 1% of daily energy intake respectively. This 
demonstrated substantial potential health benefits of a reduction in TFA intake by 1%, including saving 
approximately 10,000 hospital admissions annually[15]. This also demonstrated large potential reductions in 
pre-existing inequalities within the CHD burden[16].   
With scarce resources, the economic potential of prevention policies is increasingly important. We 
therefore aimed to quantify the potential health effects, costs and benefits of two potential UK-wide policies: 
elimination of industrial TFA only, or complete elimination (industrial and natural) of dietary intake of TFA, to 






We modelled the potential health and economic effects of elimination of all TFA, industrial and 
ruminant(reducing intake to 0%) and elimination of industrial TFA (achieving intake of 0.4% daily energy) from 
2011-2020 in the UK. Outputs include Deaths Prevented or Postponed(DPPs), Life Years Gained(LYGs), hospital 
admissions, and a societal economic perspective inclusive of direct healthcare and informal care costs and 
averted productivity loss. Industry costs are also estimated and modelled, whilst state costs in implementing 
and monitoring such policies are also accounted for. Outputs are stratified by age, gender and socio-economic 
circumstance(SEC). To create the IMPACTecon model, we extended the recently described IMPACTtfa 
model[15] calibrated for the English and Welsh population, to estimate the economic costs and benefits of 
both scenarios. Briefly, the IMPACTtfa model projects the expected number of deaths in 2011-2020 and then 
estimates the DPPs for a given reduction in TFA intake across the population. The effect size of TFA upon CHD 
mortality was taken from Mozaffarian et al[8]. Using the calculated DPPs, we calculated a reduction in hospital 
admissions and LYGs by multiplying DPPs by age, gender and CHD sub-group specific median surivials. Sub-
group specific median survival estimates were obtained from previous analysis[17,21,22,23] and updated with 
more recent data[24].  
The resulting number of surviving patients in each scenario was calculated from the mortality 
reduction percentage of each given reduction in TFA intake and existing incidence numbers by disease group. 
The relative distribution and ratios of patients across the disease groups within the underlying burden 
remained consistent from 2007[16]. We conservatively assumed a negligible effect upon case fatality itself, 
hence negligible effect upon underlying community prevalence.  
 
Data Sources for the IMPACTecon Model 
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The population was stratified into three age groups(<55, 55-74, 75+), gender and SEC (5 quintiles 
based on Index of Multiple Deprivation(IMD) scores, SEC 1 most affluent, SEC 5 most deprived). Mortality and 
demographic data for the IMPACT model was obtained from the ONS. Patient numbers were estimated for 
three mutually exclusive patient groups: acute myocardial infarction(AMI), unstable angina(UA), and heart 
failure(HF) admissions. CHD Prevalence was not included. We used Hospital Episodes Statistics, Myocardial 
Ischaemia National Audit Project and the General Practice Research Database. Intake levels of TFA were taken 
from the National Diet & Nutrition Survey[10] and Low Income Diet and Nutrition Survey[19]. We also used 
specific mortality reductions for a given reduction in TFA intake [8] stratified into age and sex specific mortality 
reductions[9]. Further details on IMPACT data sources and methodology can be obtained from Bajekal et 
al[20] and S1 file. 
We modelled four scenarios outlined in table 1.  
 
 TFA Intake TFA intake reduction SEC 
Scenario 1 (Elimination of 
all TFA, equal) 
0.8% 0.8% Equal intake 
Scenario 2 (Elimination of 
all TFA, unequal) 
0.8% 0.8% Unequal intake 
Scenario 3 (Elimination of 
industrial TFA, equal) 
0.8% 0.4% Equal intake 
Scenario 4 (Elimination of 
industrial TFA, unequal) 
0.8% 0.4% Unequal intake 
Table 1. Scenario 1, 2, 3 and 4 modelling elimination of all TFA and elimination of industrial TFA, including 
baseline TFA intake (0.8%[10]) and TFA intake reduction, both as a % of daily energy intake. Scenario 1 and 3 
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models equal TFA intake by SEC, scenarios 2 and 4 models unequal SEC quintile intake. Unequal SEC TFA intake 
is outlined in table 9. 
 
Cost Effective Analysis 
The monetary analysis takes a societal perspective, considering the state, industry, healthcare and wider 
economy monetary costs and benefits of the scenarios modelled.  
 
State costs 
We used costs relating to state monitoring of salt content as a best estimate. This was £2.4 million annually, 
comprising monitoring label contents and urine analysis of salt content[25].   For initial costs we used a range with best 
estimate of £3m (minimum-£100,000 and maximum-£5m). 
 
Industry costs 
The UK Food Standard Agency’s Impact Assessment 2009 for the voluntary reformulation strategy suggests 
£25,000 reformualtion cost per product (British Retail Consortium).  Reformulation of TFA would affect 8,000 product 
lines[26]. However, experience of  TFAs regulation in other nations, suggests that reformulation costs to industry are 
likely to be negligible[27]. We therefore modelled:  
 Worst case - Reformulation of 8,000 product lines at £25,000/product.   
 Best case - Negligible reformulation cost (phased implementation hence absorbed into product’s natural 
reformulation cycle). 
An estimated ongoing annual cost of £2million(1% maximum total capital spend) to (conservatively) account for  
reduced industry profits was included(table 8).  
Direct Healthcare Savings 
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  Costs were assigned to each treatment using data from the Department of Health reference costs 2010/11 
and The Unit Costs of Health and Social Care 2011[28].  Observed treatment uptake rates were then used to calculate 
the unit cost for each patient group.  
Productivity loss averted 
This was calculated using frictional unemployment theory described by Liu[29]. This estimates the period of 
employees’ absence from work before being replaced –90 days in the UK[29], with mean hourly wage[30], hours 
worked, and the reduction in hospital admissions for each given year to calculate the potential reduction in lost 
productivity over the period. 
 
Informal Care costs 
CHD informal care costs were estimated by using the informal care costs in the British Heart Foundation CVD 
report of £1.9bn[4] as a baseline. We reduced this sum by the corresponding proportional reduction of CHD incidence 
observed. 
Outcomes were discounted at 3.5% as per NICE guidelines[31].  
 
Outcomes 
Outcome measures included cost per LYG, and Quality Adjusted Life Years (QALYs). The cost denominator was 
state costs(not including savings) only. Health state utility values used to calculate QALYS are outlined in table 2.  
 
Table 2. Health State Utility Values. Reference: NICE guidelines [32] 
CHD subtype Health State Utility Values 
Acute Myocardial Infarction 0.88 
Unstable Angina 0.80 
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Heart Failure 0.71 
 
Baseline scenario for comparison over this 10 year period was no legislative action on TFA, assuming that CHD 
mortality would continue to reduce at the rate from 1999 -2007[16]. 
Uncertainty Analysis 
We conducted a probabilistic sensitivity analysis for parameter uncertainty with 10,000 Monte-Carlo simulation 




Elimination of all TFA resulted in the largest mortality and life years gained, with slightly larger gains when modelling 
unequal baseline TFA by SEC. CHD SEC inequalities had larger reductions assuming unequal baseline intake.   
Scenario 1 (Elimination of all TFA, equal TFA intake) 
 Eliminating all TFA could prevent approximately 3,200 deaths per year ((95% confidence interval (CI): 3,042-
3,427), gaining approximately 27,000 life years (24,578-29,953). Further, approximately 8,000 (2,800-13,024) hospital 
admissions could be averted each year (Table 3). Total hospital admissions averted over the 10 year period would be 
approximately 68,000.  
Scenario 2 (Elimination of all TFA, unequal intake) 
This scenario could prevent approximately 3,300 deaths per year (3,141-3,540), gaining approximately 29,000 
life years (26,257-31,903). This could also result in approximately 8,400 fewer hospital admissions (3,258-13,439) 
(Table 3). Total hospital admissions averted over the period would be approximately 72,000. 
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Scenario 3 (Elimination of industrial TFA, equal intake) 
This scenario could prevent approximately 1,600 deaths per year (1,521-1,714), gaining approximately 14,000 
life years (12,291-14,984). This could also result in approximately 4,000 fewer hospital admissions (-1,355-9,215)(Table 
3). Total hospital admissions averted would be approximately 34,000. 
Scenario 4 (Elimination of industrial TFA alone, unequal intake) 
This scenario could prevent approximately 1,700 deaths per year (1,619-1,825), gaining approximately 15,000 
life years (13,952-16,934). This could also result in approximately 4,400 fewer hospital admissions (-873-9,623 (Table 
3). Total hospital admissions averted would be approximately 38,000. 
 
Socio-economic inequalities 
The above potential health gains resulting from elimination of all TFA could reduce existing health inequalities. 
Conservatively estimating assuming equal intake of TFA, approximately 40% more DPPs and 80% more LYGs would be 
gained in the most deprived compared with the most affluent. When modelling a more realistic scenario (unequal 
intake), up to six times more DPPs(figure 4 S1 File) and hospital admissions could be averted and seven fold more LYGs 
could be gained in the most deprived vs. most affluent quintile. Similar proportional improvement in inequalities could 
be observed under the scenario of elimination of industrial TFA only.   
 
 
Table 3. Deaths Prevented or Postponed, Life Years Gained and hospital admissions averted in scenarios 1, 2, 3 and 4. The lower (lci) and upper (uci) 
confidence intervals are derived from 5% and 95% centiles of 10,000 Monte Carlo simulations. Since many input variables are not normally distributed 
the CI may not be symmetrical. Mean estimates are rounded. All figures above are per annum for the year 2020. 
   DPP 
 
   LYG 
 





Scenario Mean lci uci Mean lci uci Mean lci uci 
Scenario 1 3,200 3,042 3,427 27,200 24,578 29,953 8,000 2,800 13,024 
Scenario 2 3,300 3,141 3,540 29,000 26,257 31,903 8,400 3,258 13,439 
Scenario 3 1,600 1,521 1,714 13,600 12,291 14,984 4,000 -1,355 9,215 




Total state costs could range from £22million to £27.2million over the ten year period, with initial legislative 
costs ranging from £100,000 to £5million(table 4). Table 5 demonstrates that between approximately £95 million (95% 
CI: £64m - £125m) to £201 million(£139m - £262m) could be saved in direct healthcare costs as a result of reduced 
hospital admissions 2011-2020. However, financial savings to the wider economy could be substantially larger. 
Between approximately £368 million(£249m-£481m) and £727 million(£598m-£880m) could be saved in informal care 
costs(table 6), whilst the averted productivity loss to the UK economy would be between approximately £292 
million(£197m - £381m) and £613 million(£424m - £801m)(table 7).  
Table 4. Estimated legislative, annual monitoring, and total period discounted costs for scenario 1, 2,3 and 4 of reformulation or a ban on industrial 
TFA. Results are rounded to nearest £100,000. 





Minimum £100,000   £22,000,000 
Maximum £5,000,000   £27,200,000 
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Best £3,000,000 £2,400,000 £25,200,000 
Table 5. Estimated discounted direct healthcare savings over the 13 year (2007-2020) period for scenario 1, 2 and 3. The lower (lci) and upper 
confidence (uci) intervals are derived from 5% and 95% centiles of 10,000 Monte Carlo simulations. Since many input variables are not normally 
distributed the CI may not be symmetrical. Results are rounded to nearest £1,000,000 
Healthcare 
Savings Mean lci uci 
Scenario 1 £191,000,000 £155,000,000 £228,000,000 
Scenario 2 £201,000,000 £139,000,000 £262,000,000 
Scenario 3 £95,000,000 £64,000,000 £125,000,000 
Scenario 4 £105,000,000 £72,000,000 £137,000,000 
 
Table 6. Estimated discounted informal care savings over the 13 year (2007-2020) period for scenario 1, 2, 3 and 4. The lower (lci) and upper 
confidence (uci) intervals are derived from 5% and 95% centiles of 10,000 Monte Carlo simulations. Since many input variables are not normally 
distributed the CI may not be symmetrical. Results are rounded to nearest £1,000,000. 
Informal care 
saving Mean lci uci 
Scenario 1 £727,000,000 £598,000,000 £880,000,000 
Scenario 2 £557,000,000 £386,000,000 £728,000,000 
Scenario 3 £368,000,000 £249,000,000 £481,000,000 








Table 7. Estimated discounted averted productivity loss over the 13 year (2007-2020) period for scenario 1, 2, 3 and 4. The lower (lci) and upper 
confidence (uci) intervals are derived from 5% and 95% centiles of 10,000 Monte Carlo simulations. Since many input variables are not normally 
distributed the CI may not be symmetrical. Results are rounded to nearest £1,000,000. 
Productivity loss 
averted Mean lci Uci 
Scenario 1 £583,000,000 £473,000,000 £697,000,000 
Scenario 2 £613,000,000 £424,000,000 £801,000,000 
Scenario 3 £292,000,000 £197,000,000 £381,000,000 
Scenario 4 £322,000,000 £220,000,000 £418,000,000 
 
Industry Costs 
The maximum discounted cost to industry over this period could be approximately £140million, whilst the minimum 
whereby reformulation was absorbed into the natural product reformulation cycle would be £0(table 8).   
 
Table 8. Minimum and maximum industry costs in year 1, and discounted over the 10 year period. Results are rounded to nearest £1,000,000. 
  
Initial 
reformulation Period cost 
Ongoing 
annual 
cost Period Cost 
Minimum £0 £0 £0 £0 






Cost per LYG ranged across the four scenarios (S1 file table 10, figure 1) from approximately £1,400 (£1,424-
£1,469) in scenario 2 ( to approximately £3,100 (£3,071-£3,162) in scenario 3. In aggregate form, the intervention was 
most cost effective in middle aged men (55-74) at approximately £900/LYG; whilst it was the least cost effective in 
young women aged<55 at  approximately £6,600 (figure 2). 
The cost per LYG also varies substantially across SEC. Unsurprisingly; the policy was most cost effective in the 
most deprived quintile with an aggregate cost per LYG of approximately £1,200 (£1,148-£1,218), compared with 
£2,100 (£2,004-£2,133) per LYG in the most affluent in scenario 1 (elimination of al TFA, equal intake). As expected, 
this difference is even larger in scenario 2 (elimination of all TFA, unequal intake)(figure 1, S1 file table 10).  The cost 
effectiveness plane(figure 3) demonstrates each scenario to be both cost saving, and gain life years in each iteration of 
the uncertainty analysis. Further, this policy could generate between approximately 8,900(scenario 3) and 
19,300(scenario 2) QALYS over the 10 year period. As these policies are cost saving, this is the dominating policy 
against the baseline. 
Discussion 
Main finding  
A UK wide elimination of all TFA could result in substantial health gains, and NHS savings. While mortality 
gains would be greatest in the elderly, a large number of life years would be gained in the younger age groups. 
All TFA policies modelled would be cost effective, however elimination of all TFA could be ‘extremely 
cost effective’ (a WHO definition for policies costing less than per capita GDP). This model suggests that elimination 
of all TFA would be more effective than the baseline (no ban) and cost saving, hence the dominant scenario. A 
comparison of TFA cost effectiveness with statins as a primary prevention might further inform policy makers. 
Fidan et al[17] found statins to be ‘reasonably cost effective’ for secondary prevention, but ‘much less cost 
effective’ for primary prevention with an aggregate cost per LYG of £27,828. This compares with an aggregate 
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cost of between approximately £1,400 and £3,100 per LYG in the four scenarios we have modelled.  NICE lipid 
lowering guidelines[31] when taking a 10 year view (as in our study) estimates cost effectiveness of statins 
varied from £36,000-£286,000 per QALY for those aged 45, increasing to £53,000-£367,000 per QALY for those 
aged 85. Even in the conservative scenario of calculating cost per QALY using costs only, each QALY would only 
cost £1,300 (scenario 2) to £2,800 (scenario 3).  
Socio-economic inequalities 
The effect upon CHD inequalities could be substantial, with five times greater reduction in deaths and 
LYG in the most deprived groups, than the most affluent.  This policy would be most cost effective in the least 
affluent groups.  Furthermore, the individual economic benefits, such as less time out of the workforce, and 
lower rates of early retirement due to ill health are not modelled here but would likely be substantial.   
 
What is already known on this topic 
Our health and cost effectiveness outcomes results are consistent with previous studies. Mozaffarian et al[33] 
analysed TFA consumption in Iran. Baseline intake of trans fats was 5-6 times above effective elimination, than in the 
UK, whilst baseline CHD mortality rates were also higher. This study suggested that elimination of industrial TFA could 
prevent 5,600-27,300 CHD deaths. These modelling results are also consistent with the large(50%) reductions in CHD 
mortality observed in Denmark where TFA intake has been reduced from 6g per day to 1g per day[9] as well as 
estimates made in the NICE guidelines of a potential 4,500-7000 lives saved by reducing TFA in the UK[34]. Barton et 
al[18] proposed that a 0.5% reduction in TFA intake (as a percentage of daily energy intake) might save 
approximately 2,700 deaths and £235million annually and gain 754,000 QALYS over a decade. However, this 
analysis did not take into account costs incurred in introducing and monitoring a policy, nor any industry costs.  
What this study adds 
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Our study has implications for policy and future research. Firstly, the policy could save lives, money 
and reduce CHD inequalities. Importantly, cost effectiveness can be compared with healthcare policies across 
several countries due to reporting in PPP dollars.  
 
Strengths and Limitations 
This modelling study has several strengths. The modelling uses large data sets which cover the entire England 
and Wales adult population of 35 million. Data quality is generally very good[20,35,36,37]. Further, this study includes 
a wide range of potential cost sources including government and industry costs, whilst also accounting for cost savings 
in healthcare, informal care, and productivity, as well as reporting several cost effectiveness measures. The datasets 
used are representative of the SEC distribution of the English and Welsh population.  
This study also has several limitations. We used an area level categorisation of SEC (IMD). This might therefore 
be considered sub-optimal for analysing trends within individuals but generally correlates well with measures of 
individual socioeconomic position[20]. Further, this model assumes immediate health benefits. However, rapid 
improvements might reasonably be expected[38].  Whilst the scenarios eliminating industrial TFA only (3 and 4) model 
an elimination of industrial TFA, scenarios 1 and 2 model a total elimination of TFA, including ruminant TFA. The 
harmful effects of ruminant TFA are less well documented than industrial TFA, however this is now less clear[7]. We 
assume equal mortality gains from ruminant elimination as industrial. This scenario is useful to quantify the total 
disease burden, however is a politically idealistic target, more feasible in vegan populations than the general 
population. Reformulation cost estimates range greatly, whilst the Danish Veterinary and Food Administration 
understood the reformulation costs to the industry to be negligible[27]. We therefore modelled best and worst case 





This study provides quantitative health and economic measures, to better inform policy makers. Population 
based prevention policies such as eliminating industrial TFA may generate substantial health and inequalities gains, as 










Figure 1. Cost per Life Year Gained in scenario 1, 2,3 and 4 over the period 2011-2020. Life Years Gained stratified by 
Socio-economic quintile. Data source: Hospital Episode Statistics 
 
 
Figure 2a. Cost per Life Year Gained in scenario 1 (TFA intake equal at 0.8% across Socio-economic circumstance  
quintiles), of eliminating all  TFA, achieving TFA intake of 0% daily energy in males. Life Years Gained  stratified  by age, 
and Socio-economic quintile over the  period 2011-2020. Data source: Hospital Episode Statistics 
 
Figure 2b. Cost per Life Year Gained in scenario 1 (TFA intake equal at 0.8% across Socio-economic circumstance  
quintiles), of eliminating all  TFA, achieving TFA intake of 0% daily energy in females. Life Years Gained  stratified  by 





Figure 3. Cost effectiveness plane. Outputs from 10,000 iterations of Probabilistic Sensitivity Analysis of Life  
Years Gained plotted against incremental cost (state costs and direct healthcare savings only) of policy for  





Table 9 – TFA intake (as a % of daily energy) by socio-economic circumstance (SEC) quintile. Figures used in scenarios 2 and 4, whereas scenarios 1 and 3 
assume equal TFA intake by SEC. Data Source:  Adapted from National Diet and nutrition survey [10] and Low Income Dietary survey [19] 
  SEC 1 SEC 2 SEC 3 SEC 4 SEC 5 
Trans fats 
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